Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Eli Lilly and Company
Sichuan Enray Pharmaceutical Sciences Company
University of Arizona
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Eli Lilly and Company
Inhibrx Biosciences, Inc
Eli Lilly and Company
University of Kansas Medical Center
A2 Biotherapeutics Inc.
Palleon Pharmaceuticals, Inc.
NuCana plc
Turning Point Therapeutics, Inc.
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
Cancer Research UK
Hoffmann-La Roche
Numab Therapeutics AG
Xynomic Pharmaceuticals, Inc.
Intensity Therapeutics, Inc.
Cyteir Therapeutics, Inc.
Aminex Therapeutics, Inc.
Simcha IL-18, Inc.
Atara Biotherapeutics
Salubris Biotherapeutics Inc
GlaxoSmithKline
Cancer Research UK
SQZ Biotechnologies
CytomX Therapeutics
CytomX Therapeutics
OncoResponse, Inc.
Kineta Inc.
Advaxis, Inc.
Genocea Biosciences, Inc.
Eisai Inc.
Royal Marsden NHS Foundation Trust
NKGen Biotech, Inc.
Effector Therapeutics
Daiichi Sankyo
Tactile Medical
National Institutes of Health Clinical Center (CC)
University of Alabama at Birmingham
GenVec
GenVec
Swedish Orphan Biovitrum
University of Plymouth